Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).

Revvity said on Monday it has received a CE-IVD mark for a molecular testing platform that can be used to screen newborns for spinal muscular atrophy and severe combined immunodeficiency.

In 2023, NHC and 10 other departments issued the Action Plan Towards the Elimination of Cervical Cancer (2023-2030). The goal is that by 2025, HPV vaccination services for girls of school age will be promoted on a pilot basis, the cervical cancer screening rate for women of school age will reach 50%, and the treatment rate for patients with cervical cancer and precancerous lesions will reach 90%.

Based on the advantages of their respective fields, the two companies will carry out in-depth cooperation in life information and support, in vitro diagnosis, medical imaging, overall solutions for two cancer screening, hospital department equipment, information construction, etc., and jointly establish the "Hybribio-Mindray Standardized Laboratory" to achieve complementary advantages and resource sharing.

Roche announced that the cobas® HPV test for use on the cobas® 6800/8800 Systems has been awarded World Health Organization (WHO) prequalification. WHO prequalification expands the availability of this critical HPV screening tool in countries that rely on the global organisation’s list in making purchasing and implementation decisions.

Pillar Biosciences said on Thursday that it has acquired a nonexclusive license to high-throughput screening-related intellectual property from Dutch ag-bio firm KeyGene.

BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya.

On March 27, 2023, MGI and Fujian Berry Oncology Co., Ltd. signed the strategic cooperation agreement.

Biocartis said Thursday that it has secured US Food and Drug Administration 510(k) clearance for a microsatellite instability (MSI) assay to screen for Lynch syndrome in colorectal cancer patients.

Genetron Health on Tuesday reported a 38 percent year-over-year increase in its second quarter revenues amid strong growth in sales from its LDT and IVD segments.